Core Laboratories (CLB) Aktienübersicht
Core Laboratories Inc. bietet der Öl- und Gasindustrie in den Vereinigten Staaten und international Dienstleistungen und Produkte zur Beschreibung von Lagerstätten und zur Verbesserung der Produktion an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
CLB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Core Laboratories Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$10.99 |
| 52-Wochen-Hoch | US$20.36 |
| 52-Wochen-Tief | US$9.72 |
| Beta | 1.01 |
| 1 Monat Veränderung | -17.18% |
| 3 Monate Veränderung | -33.43% |
| 1 Jahr Veränderung | -15.07% |
| 3 Jahre Veränderung | -54.57% |
| 5 Jahre Veränderung | -68.62% |
| Veränderung seit IPO | 266.33% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 22
CLB: Refined Assumptions Will Support Undervalued Shares And Future P/E
Analysts have reaffirmed their $22.00 price target on Core Laboratories, citing updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E that refine but do not materially alter their prior valuation view. What’s in the News for Core Laboratories No recent Core Laboratories specific news items were identified in the provided sources.
Narrativ-Update • Jun 07
CLB: Future Middle East Recovery Will Support Reservoir Description Led Upside Potential
Analysts have revised their price target for Core Laboratories to $16.33, with the change supported by updated assumptions around a 7.59% discount rate, 1.85% revenue growth, a 6.35% profit margin, and a future P/E of 24.86x. What's in the News Core Laboratories revised its earnings guidance for the first quarter of 2026, indicating that revenue and earnings are expected to be below the guidance issued on 4 February 2026.Narrativ-Update • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).Recent updates
Narrativ-Update • Jun 22
CLB: Refined Assumptions Will Support Undervalued Shares And Future P/E
Analysts have reaffirmed their $22.00 price target on Core Laboratories, citing updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E that refine but do not materially alter their prior valuation view. What’s in the News for Core Laboratories No recent Core Laboratories specific news items were identified in the provided sources.Narrativ-Update • Jun 07
CLB: Future Middle East Recovery Will Support Reservoir Description Led Upside Potential
Analysts have revised their price target for Core Laboratories to $16.33, with the change supported by updated assumptions around a 7.59% discount rate, 1.85% revenue growth, a 6.35% profit margin, and a future P/E of 24.86x. What's in the News Core Laboratories revised its earnings guidance for the first quarter of 2026, indicating that revenue and earnings are expected to be below the guidance issued on 4 February 2026.Narrativ-Update • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).Narrativ-Update • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).Narrativ-Update • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaNarrativ-Update • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.Narrativ-Update • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.Narrativ-Update • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.Analyseartikel • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...Narrativ-Update • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Analyseartikel • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analyseartikel • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...Analyseartikel • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...Analyseartikel • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...Analyseartikel • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Analyseartikel • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyseartikel • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Neues Narrativ • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Analyseartikel • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyseartikel • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...Analyseartikel • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...Aktionärsrenditen
| CLB | US Energy Services | US Markt | |
|---|---|---|---|
| 7D | -4.1% | 4.5% | 0.6% |
| 1Y | -15.1% | 47.2% | 19.5% |
Rendite im Vergleich zur Industrie: CLB unter dem Niveau der Branche US Energy Services , die im vergangenen Jahr eine Rendite von 47.2% erzielte.
Rendite vs. Markt: CLB hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| CLB volatility | |
|---|---|
| CLB Average Weekly Movement | 7.6% |
| Energy Services Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: CLB hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CLBDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1936 | 3,300 | Larry Bruno | www.corelab.com |
Core Laboratories Inc. bietet Dienstleistungen und Produkte zur Beschreibung von Lagerstätten und zur Produktionssteigerung für die Öl- und Gasindustrie in den Vereinigten Staaten und international an. Das Unternehmen ist in den Segmenten Lagerstättenbeschreibung und Produktionsverbesserung tätig. Das Segment Lagerstättenbeschreibung umfasst die Charakterisierung von Gesteins- und Flüssigkeitsproben aus Erdöllagerstätten, um die Produktion zu steigern und die Gewinnung von Erdöl und Erdgas aus den Lagerstätten der Kunden zu verbessern.
Core Laboratories Inc.'s Grundlagenzusammenfassung
| CLB grundlegende Statistiken | |
|---|---|
| Marktanteil | US$513.98m |
| Gewinn(TTM) | US$29.03m |
| Umsatz(TTM) | US$524.73m |
17.4x
Kurs-Gewinn-Verhältnis 1.0x
Kurs-Umsatz-VerhältnisIst CLB zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CLB Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$524.73m |
| Kosten der Einnahmen | US$420.19m |
| Bruttogewinn | US$104.54m |
| Sonstige Ausgaben | US$75.51m |
| Gewinn | US$29.03m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 29, 2026
| Gewinn per Aktie (EPS) | 0.63 |
| Bruttomarge | 19.92% |
| Nettogewinnspanne | 5.53% |
| Schulden/Eigenkapital-Verhältnis | 41.6% |
Wie hat sich CLB auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.4%
Aktuelle Dividendenrendite6%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 17:01 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Core Laboratories Inc. wird von 30 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |